AFT Pharmaceuticals Ltd. (AFT) Stock Price & Analysis

AFT Stock Chart & Stats

NZ$4.60-NZ$0.05(-1.08%)

At close: Nov 02 4:59 PM GMT+13

Day’s Range: NZD 4.60 - NZD 4.65
52-Week Range: NZD 3.02 - NZD 4.85
Previous Close: NZD 4.65
Volume: N/A
Average Volume (3M): 19.65K
Market Cap: NZD 487.67M
Enterprise Value: NZD 395.00M
Total Cash (Recent Filing): NZD 10.24M
Total Debt (Recent Filing): NZD 54.11M
Price to Earnings (P/E): 32.5
Beta: -0.00
Next Earnings: Nov 19, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Jun 18, 2026
Dividend Yield: 0.63%

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

A sustained rise in revenue across five annual periods indicates expanding product adoption and international commercial reach. The latest acceleration, together with growth across territories, provides a stronger foundation for reinvestment, operating leverage, and continued scale over the next several quarters.

Differentiated R&D Pipeline

The combination of patented projects, injectable products, and room-temperature formulations gives AFT multiple routes to future growth beyond its current portfolio. A broader intellectual-property pipeline can support licensing income, product launches, and stronger competitive positioning in specialty pharmaceutical markets.

Expansion Of Maxigesic Franchise

The Japan agreement extends AFT’s flagship non-opioid pain franchise into a major pharmaceutical market while combining development, supply, milestone, royalty, and sales opportunities. Using a local specialist for submissions and commercialisation can broaden distribution without requiring AFT to build the entire market infrastructure itself.

Bears Say

Negative Cash Generation

The reversal to negative operating and free cash flow weakens cash conversion and increases reliance on external financing or balance-sheet resources. Until generation normalises, AFT has less flexibility to fund product development, absorb execution setbacks, or pursue growth while maintaining financial resilience.

Sharp Debt Increase

Although debt-to-equity remains manageable at about 0.49, the rapid year-on-year increase reduces financial flexibility, particularly alongside negative free cash flow. Greater borrowing can constrain future investment and make earnings or cash-flow weakness more consequential if the current build persists.

Profitability Compression

Declining net margin shows that strong revenue growth is not translating into earnings at the earlier rate. Continued cost, mix, or investment pressure could limit operating leverage, reduce internally funded expansion, and make future profit delivery more dependent on successful launches and commercial execution.

AFT Pharmaceuticals Ltd. News

AFT Pharmaceuticals posts strong 1H growth and deepens global R&D pipeline

An announcement from AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) is now available. AFT Pharmaceuticals reported sustained double-digit revenue growth across all divisions in the first half of FY27, saying it

4w agoAFP AFT

AFT Pharmaceuticals licenses Maxigesic IV to Mikasa for Japanese market push

The latest announcement is out from AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ). AFT Pharmaceuticals has signed an exclusive development, licensing and supply deal with Japan’s MIKASASEIYAKU for Maxigesic IV, its

1M agoAFP AFT

AFT Pharmaceuticals Shareholders Back Board at 2026 AGM

AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) has issued an update. Shareholders of AFT Pharmaceuticals approved all resolutions at the company’s 2026 Annual Shareholders’ Meeting held in Auckland, New Zealand. The

3M agoAFP AFT

AFT Pharmaceuticals Chair David Flacks to Step Down After Steering Years of Strong Growth

AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) has shared an announcement. AFT Pharmaceuticals, a New Zealand-based multinational drug developer and distributor, has built a diversified portfolio of patented, branded, and generic

3M agoAFP AFT

AFT Pharmaceuticals posts record year, lifts dividend and maps next growth phase

AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) has provided an update. AFT Pharmaceuticals reported another record year, with revenue up 22% to $254.7 million and operating profit up 39% to $24.4

3M agoAFP AFT

AFT Pharmaceuticals touts R&D pipeline with multi-billion-dollar market reach

AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) has shared an update. AFT Pharmaceuticals is showcasing its research and development portfolio to investors, highlighting eight patented projects, 24 off-patent injectables and other

3M agoAFP AFT

Pitt St Research Begins Coverage on New Zealand’s AFT Pharmaceuticals

AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) has provided an update. AFT Pharmaceuticals, a New Zealand-based multinational drug maker listed on NZX and ASX, develops and distributes a mix of patented,

3M agoAFP AFT

AFT Pharmaceuticals Secures Tentative FDA Nod for Scomara, Eyes Growth Outside U.S.

An announcement from AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) is now available. AFT Pharmaceuticals has received tentative U.S. FDA approval for Scomara, a rapamycin 0.5% cream for treating facial angiofibromas

3M agoAFP AFT

AFT Pharmaceuticals Flags Strong Growth as Injectables Pipeline Advances

An update from AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ) is now available. AFT Pharmaceuticals has reported sustained first-quarter growth for FY27 and says it remains on track to reach its

3M agoAFP AFT

AFT Pharmaceuticals Sets 31 July Date for 2026 Annual Meeting

The latest update is out from AFT Pharmaceuticals Ltd. ( ($NZ:AFT) ). AFT Pharmaceuticals has called its Annual Meeting of Shareholders for 31 July 2026 at the Milford Cruising Club

4M agoAFP AFT

AFT FAQ

What was AFT Pharmaceuticals Ltd.’s price range in the past 12 months?

AFT Pharmaceuticals Ltd. lowest stock price was NZ$3.02 and its highest was NZ$4.85 in the past 12 months.

What is AFT Pharmaceuticals Ltd.’s market cap?

AFT Pharmaceuticals Ltd.’s market cap is NZ$487.67M.

When is AFT Pharmaceuticals Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were AFT Pharmaceuticals Ltd.’s earnings last quarter?

AFT Pharmaceuticals Ltd. released its earnings results on May 20, 2026. The company reported NZ$0.109 earnings per share for the quarter.

Is AFT Pharmaceuticals Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does AFT Pharmaceuticals Ltd. pay dividends?

AFT Pharmaceuticals Ltd. pays a ― dividend of NZ$0.025 which represents an annual dividend yield of 0.63%. See more information on AFT Pharmaceuticals Ltd. dividends here

What is AFT Pharmaceuticals Ltd.’s EPS estimate?

AFT Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AFT Pharmaceuticals Ltd. have?

AFT Pharmaceuticals Ltd. has 104,874,660 shares outstanding.

What happened to AFT Pharmaceuticals Ltd.’s price movement after its last earnings report?

AFT Pharmaceuticals Ltd. reported an EPS of NZ$0.109 in its last earnings report. Following the earnings report the stock price went up 7.622%.

Which hedge fund is a major shareholder of AFT Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in NZ:AFT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description